Literature DB >> 32361941

Molecular characteristics and clinical outcomes of elderly patients with IDH-wildtype glioblastomas: comparative study of older and younger cases in Kansai Network cohort.

Junya Fukai1,2, Hideyuki Arita3,4, Toru Umehara3,5, Ema Yoshioka3,6, Tomoko Shofuda3,6, Daisuke Kanematsu3,7, Yoshinori Kodama3,8, Masayuki Mano3,9, Manabu Kinoshita3,5, Yoshiko Okita3,10,11, Masahiro Nonaka3,12, Takehiro Uda3,13, Naohiro Tsuyuguchi3,13,14, Daisuke Sakamoto3,15, Yuji Uematsu16,3, Naoyuki Nakao16,3, Kanji Mori3,17, Yonehiro Kanemura3,7,11.   

Abstract

Aging is a known negative prognostic factor in glioblastomas (GBM). Whether particular genetic backgrounds are a factor in poor outcomes of elderly patients with GBM warrants investigation. We aim to elucidate any differences between older and younger adult patients with IDH-wildtype GBM regarding both molecular characteristics and clinical outcomes. We collected adult cases diagnosed with IDH-wildtype GBM from the Kansai Network. Clinical and pathological characteristics were analyzed retrospectively and compared between older (≥ 70 years) and younger (≤ 50 years) cases. Included were 92 older vs. 33 younger cases. The older group included more patients with preoperative Karnofsky performance status score < 70 and had a shorter survival time than the younger group. MGMT promoter was methylated more frequently in the older group. TERT promoter mutation was more common in the older group. There were significant differences in DNA copy-number alteration profiles between age groups in PTEN deletion and CDK4 amplification/gain. In the older group, no molecular markers were identified, but surgical resection was an independent prognostic factor. Age-specific survival difference was significant in the MGMT methylated and TERT wildtype subgroup. Elderly patients have several potential factors in poor prognosis of glioblastomas. Varying molecular profiles may explain differing rates of survival between generations.

Entities:  

Keywords:  Elderly; IDH-wildtype glioblastoma; Molecular marker; Overall survival

Year:  2020        PMID: 32361941     DOI: 10.1007/s10014-020-00363-1

Source DB:  PubMed          Journal:  Brain Tumor Pathol        ISSN: 1433-7398            Impact factor:   3.298


  6 in total

Review 1.  Prognostic significance of TERT promoter mutations in adult-type diffuse gliomas.

Authors:  Hideyuki Arita; Koichi Ichimura
Journal:  Brain Tumor Pathol       Date:  2022-01-31       Impact factor: 3.298

2.  TERT promoter mutation associated with multifocal phenotype and poor prognosis in patients with IDH wild-type glioblastoma.

Authors:  Zensho Kikuchi; Ichiyo Shibahara; Tetsu Yamaki; Ema Yoshioka; Tomoko Shofuda; Rintaro Ohe; Ken-Ichiro Matsuda; Ryuta Saito; Masayuki Kanamori; Yonehiro Kanemura; Toshihiro Kumabe; Teiji Tominaga; Yukihiko Sonoda
Journal:  Neurooncol Adv       Date:  2020-09-01

Review 3.  Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System.

Authors:  Takashi Komori
Journal:  Lab Invest       Date:  2021-09-09       Impact factor: 5.662

4.  Genomic and molecular features distinguish young adult cancer from later-onset cancer.

Authors:  William Lee; Zishan Wang; Miriam Saffern; Tomi Jun; Kuan-Lin Huang
Journal:  Cell Rep       Date:  2021-11-16       Impact factor: 9.423

Review 5.  Newly Diagnosed Glioblastoma in Elderly Patients.

Authors:  Carlen A Yuen; Marissa Barbaro; Aya Haggiagi
Journal:  Curr Oncol Rep       Date:  2022-02-05       Impact factor: 5.945

Review 6.  Glioblastoma in the Elderly: Review of Molecular and Therapeutic Aspects.

Authors:  Francesco Bruno; Alessia Pellerino; Rosa Palmiero; Luca Bertero; Cristina Mantovani; Diego Garbossa; Riccardo Soffietti; Roberta Rudà
Journal:  Biomedicines       Date:  2022-03-10
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.